Statement: the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib. urinary system findings reference identifier is a character or string that represents a urinary system findings event reference.
Primary_evidence: INTERVENTION 1:    Lapatinib 1250 mg and Capecitabine 2000 mg/m^2   Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.